PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28303105-0 2017 Caloric Restriction Is More Efficient than Physical Exercise to Protect from Cisplatin Nephrotoxicity via PPAR-Alpha Activation. Cisplatin 77-86 peroxisome proliferator activated receptor alpha Mus musculus 106-116 33049997-0 2020 PPAR-alpha Deletion Attenuates Cisplatin Nephrotoxicity by Modulating Renal Organic Transporters MATE-1 and OCT-2. Cisplatin 31-40 peroxisome proliferator activated receptor alpha Mus musculus 0-10 33049997-8 2020 Considering the above, we treated wild-type and PPAR-alpha knockout mice with cisplatin in order to evaluate the severity of nephrotoxicity. Cisplatin 78-87 peroxisome proliferator activated receptor alpha Mus musculus 48-58 33049997-12 2020 Here, we show for the first time that PPAR-alpha deletion protects against cisplatin nephrotoxicity and that this protection is via modulation of the organic transporters MATE-1 and OCT-2. Cisplatin 75-84 peroxisome proliferator activated receptor alpha Mus musculus 38-48 20858838-9 2010 Cisplatin did not directly inhibit the transport of carnitine by Octn2 but downregulated multiple target genes of the transcription factor peroxisome proliferator activated receptor alpha, including Slc22a5, in the kidney of wild-type mice that were absent in Oct1/2(-/-) mice. Cisplatin 0-9 peroxisome proliferator activated receptor alpha Mus musculus 139-187 22622461-1 2012 Peroxisome proliferator-activated receptor-alpha (PPARalpha) activation attenuates cisplatin (CP)-mediated acute kidney injury by increasing fatty acid oxidation, but mechanisms leading to reduced renal triglyceride (TG) accumulation could also contribute. Cisplatin 83-92 peroxisome proliferator activated receptor alpha Mus musculus 0-48 22622461-1 2012 Peroxisome proliferator-activated receptor-alpha (PPARalpha) activation attenuates cisplatin (CP)-mediated acute kidney injury by increasing fatty acid oxidation, but mechanisms leading to reduced renal triglyceride (TG) accumulation could also contribute. Cisplatin 83-92 peroxisome proliferator activated receptor alpha Mus musculus 50-59 15814532-1 2005 Recently, we demonstrated that peroxisome proliferator-activated receptor-alpha (PPARalpha) ligand ameliorates cisplatin-induced acute renal failure (ARF) by preventing inhibition of substrate oxidation, and also by preventing apoptosis and necrosis of the proximal tubule (Li S, Bhatt R, Megyesi J, Gokden N, Shah SV, and Portilla D. Am J Physiol Renal Physiol 287: F990-F998, 2004). Cisplatin 111-120 peroxisome proliferator activated receptor alpha Mus musculus 31-79 19710628-3 2009 Segment-specific upregulation of PPARalpha expression by testosterone treatment of female transgenic mice improved kidney function during cisplatin or ischemia-reperfusion-induced acute kidney injury. Cisplatin 138-147 peroxisome proliferator activated receptor alpha Mus musculus 33-42 19876055-3 2009 have demonstrated that proximal tubule-restricted peroxisome proliferator-activated receptor-alpha (PPARalpha) expression in transgenic mice reduced cisplatin- and ischemia/reperfusion-induced acute renal injury. Cisplatin 149-158 peroxisome proliferator activated receptor alpha Mus musculus 50-98 19876055-3 2009 have demonstrated that proximal tubule-restricted peroxisome proliferator-activated receptor-alpha (PPARalpha) expression in transgenic mice reduced cisplatin- and ischemia/reperfusion-induced acute renal injury. Cisplatin 149-158 peroxisome proliferator activated receptor alpha Mus musculus 100-109 18368030-1 2008 Fibrates, the PPAR alpha ligand-like compounds increase the expression of proximal tubule liver fatty acid binding protein (L-FABP) and significantly decrease cisplatin-induced acute kidney injury. Cisplatin 159-168 peroxisome proliferator activated receptor alpha Mus musculus 14-24 16672910-11 2006 Our study shows that cisplatin-induces a unique NMR metabolic profile in urine of mice that developed acute renal failure, and confirms the protective effect of a fibrate class of PPARalpha ligands. Cisplatin 21-30 peroxisome proliferator activated receptor alpha Mus musculus 180-189 15814532-1 2005 Recently, we demonstrated that peroxisome proliferator-activated receptor-alpha (PPARalpha) ligand ameliorates cisplatin-induced acute renal failure (ARF) by preventing inhibition of substrate oxidation, and also by preventing apoptosis and necrosis of the proximal tubule (Li S, Bhatt R, Megyesi J, Gokden N, Shah SV, and Portilla D. Am J Physiol Renal Physiol 287: F990-F998, 2004). Cisplatin 111-120 peroxisome proliferator activated receptor alpha Mus musculus 81-90 15814532-2 2005 In the following studies, we examined the protective effect of PPARalpha ligand on cisplatin-induced inflammatory responses during ARF. Cisplatin 83-92 peroxisome proliferator activated receptor alpha Mus musculus 63-72 15814532-6 2005 Pretreatment of wild-type mice with WY-14,643, a fibrate class of PPARalpha ligands, before cisplatin significantly suppressed cisplatin-induced upregulation of cytokine/chemokine expression, prevented neutrophil accumulation, and ameliorated renal dysfunction. Cisplatin 127-136 peroxisome proliferator activated receptor alpha Mus musculus 66-75 15814532-8 2005 In addition, we observed that cisplatin-induced NF-kappaB binding activity in nuclear extracts from wild-type mice was markedly reduced by treatment with PPARalpha ligand. Cisplatin 30-39 peroxisome proliferator activated receptor alpha Mus musculus 154-163 15814532-9 2005 These results demonstrate that PPARalpha exerts an anti-inflammatory effect in kidney tissue by a mechanism that includes inhibition of NF-kappaB DNA binding activity, and this effect results in inhibition of neutrophil infiltration, cytokine/chemokine release, and amelioration of cisplatin-induced ARF. Cisplatin 282-291 peroxisome proliferator activated receptor alpha Mus musculus 31-40 12234291-0 2002 Alterations of PPARalpha and its coactivator PGC-1 in cisplatin-induced acute renal failure. Cisplatin 54-63 peroxisome proliferator activated receptor alpha Mus musculus 15-24 15280156-0 2004 PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. Cisplatin 62-71 peroxisome proliferator activated receptor alpha Mus musculus 0-10 15280156-2 2004 Recently, we demonstrated that cisplatin-induced inhibition of substrate oxidation can be reversed by the administration of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) ligands, resulting in amelioration of renal function. Cisplatin 31-40 peroxisome proliferator activated receptor alpha Mus musculus 124-172 15280156-2 2004 Recently, we demonstrated that cisplatin-induced inhibition of substrate oxidation can be reversed by the administration of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) ligands, resulting in amelioration of renal function. Cisplatin 31-40 peroxisome proliferator activated receptor alpha Mus musculus 174-184 15280156-7 2004 Pretreatment of PPAR-alpha wild-type mice with PPAR-alpha ligand WY-14643 reduced significantly cisplatin-induced increased protein expression and enzyme activity of Endo G and prevented the nuclear translocation of mitochondrial Endo G. Cisplatin 96-105 peroxisome proliferator activated receptor alpha Mus musculus 16-26 15280156-7 2004 Pretreatment of PPAR-alpha wild-type mice with PPAR-alpha ligand WY-14643 reduced significantly cisplatin-induced increased protein expression and enzyme activity of Endo G and prevented the nuclear translocation of mitochondrial Endo G. Cisplatin 96-105 peroxisome proliferator activated receptor alpha Mus musculus 47-57 15280156-8 2004 Morphological examination of tubular injury in the PPAR-alpha wild-type mice that received PPAR-alpha ligand and cisplatin did show significant amelioration of acute tubular necrosis, as well as a significant reduction in the number of apoptotic cells in the proximal tubule when compared with the cisplatin-treated group. Cisplatin 113-122 peroxisome proliferator activated receptor alpha Mus musculus 51-61 15280156-8 2004 Morphological examination of tubular injury in the PPAR-alpha wild-type mice that received PPAR-alpha ligand and cisplatin did show significant amelioration of acute tubular necrosis, as well as a significant reduction in the number of apoptotic cells in the proximal tubule when compared with the cisplatin-treated group. Cisplatin 298-307 peroxisome proliferator activated receptor alpha Mus musculus 91-101 15280156-9 2004 In contrast, in PPAR-alpha-null mice treated with the ligand and cisplatin, Endo G protein expression was not reduced and this was accompanied by lack of protection of kidney function. Cisplatin 65-74 peroxisome proliferator activated receptor alpha Mus musculus 16-26 15280156-10 2004 We conclude that PPAR-alpha ligand protects against cisplatin-induced renal injury via a PPAR-alpha-dependent mechanism by reducing the expression and enzyme activity of proximal tubule Endo G, which results in amelioration of both proximal tubule cell apoptosis and necrosis. Cisplatin 52-61 peroxisome proliferator activated receptor alpha Mus musculus 17-27 15280156-10 2004 We conclude that PPAR-alpha ligand protects against cisplatin-induced renal injury via a PPAR-alpha-dependent mechanism by reducing the expression and enzyme activity of proximal tubule Endo G, which results in amelioration of both proximal tubule cell apoptosis and necrosis. Cisplatin 52-61 peroxisome proliferator activated receptor alpha Mus musculus 89-99 14612380-0 2004 PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Cisplatin 34-43 peroxisome proliferator activated receptor alpha Mus musculus 0-10 14612380-2 2004 We now report on the effects of peroxisome proliferator-activated receptor-alpha (PPAR alpha) ligand Wy-14643 (WY) on the abnormalities of medium chain fatty acid oxidation and pyruvate dehydrogenase complex (PDC) activity in kidney tissue of cisplatin-treated mice. Cisplatin 243-252 peroxisome proliferator activated receptor alpha Mus musculus 32-80 14612380-2 2004 We now report on the effects of peroxisome proliferator-activated receptor-alpha (PPAR alpha) ligand Wy-14643 (WY) on the abnormalities of medium chain fatty acid oxidation and pyruvate dehydrogenase complex (PDC) activity in kidney tissue of cisplatin-treated mice. Cisplatin 243-252 peroxisome proliferator activated receptor alpha Mus musculus 82-92 14612380-4 2004 PPAR alpha ligand WY ameliorated cisplatin-induced acute renal failure and prevented cisplatin-induced reduction of mRNA levels and enzyme activity of MCAD. Cisplatin 33-42 peroxisome proliferator activated receptor alpha Mus musculus 0-10 14612380-4 2004 PPAR alpha ligand WY ameliorated cisplatin-induced acute renal failure and prevented cisplatin-induced reduction of mRNA levels and enzyme activity of MCAD. Cisplatin 85-94 peroxisome proliferator activated receptor alpha Mus musculus 0-10 14612380-5 2004 In contrast, in cisplatin-treated PPAR alpha null mice, WY did not protect kidney function and did not reverse cisplatin-induced decreased expression of MCAD. Cisplatin 16-25 peroxisome proliferator activated receptor alpha Mus musculus 34-44 14612380-6 2004 Cisplatin inhibited renal PDC activity before the development of acute tubular necrosis, and PDC inhibition was reversed by pretreatment with PPAR alpha agonist WY. Cisplatin 0-9 peroxisome proliferator activated receptor alpha Mus musculus 142-152 14612380-7 2004 Cisplatin also induced increased mRNA and protein levels of pyruvate dehydrogenase kinase-4 (PDK4), and PPAR alpha ligand WY prevented cisplatin-induced increased expression of PDK4 protein levels in wild-type mice. Cisplatin 135-144 peroxisome proliferator activated receptor alpha Mus musculus 104-114 14612380-8 2004 We conclude that PPAR alpha agonists have therapeutic potential for cisplatin-induced acute renal failure. Cisplatin 68-77 peroxisome proliferator activated receptor alpha Mus musculus 17-27 14612380-9 2004 Use of PPAR alpha ligands prevents acute tubular necrosis by ameliorating cisplatin-induced inhibition of two distinct metabolic processes, MCAD-mediated fatty acid oxidation and PDC activity. Cisplatin 74-83 peroxisome proliferator activated receptor alpha Mus musculus 7-17 13680532-4 2003 Pretreatment with PPARalpha ligands restores the expression and activity of renal FAO enzymes, and this metabolic alteration leads to amelioration of acute tubular necrosis caused by ischemia/reperfusion or cisplatin-induced ARF. Cisplatin 207-216 peroxisome proliferator activated receptor alpha Mus musculus 18-27 12234291-1 2002 BACKGROUND: In this study we examined whether a recently characterized coactivator of Peroxisome proliferator activated receptor alpha (PPARalpha), Peroxisome proliferator activated receptor-gamma-coactivator-1 (PGC-1) plays a role in the regulation of fatty acid oxidation during cisplatin-induced nephrotoxicity. Cisplatin 281-290 peroxisome proliferator activated receptor alpha Mus musculus 86-134 12234291-4 2002 Eletrophoretic mobility shift assays (EMSA) and Western blot analysis of nuclear extracts, and transient transfection of PGC-1 were used to examine the effect of cisplatin on PPARalpha-regulated fatty acid oxidation. Cisplatin 162-171 peroxisome proliferator activated receptor alpha Mus musculus 175-184 12234291-6 2002 DNA-protein binding studies demonstrated that exposure to cisplatin reduces PPARalpha/retinoid X receptor (RXRalpha) binding activity. Cisplatin 58-67 peroxisome proliferator activated receptor alpha Mus musculus 76-85 12234291-11 2002 CONCLUSIONS: These results demonstrate that cisplatin deactivates PPARalpha by reducing its DNA binding activity and the availability of its tissue specific coactivator PGC-1. Cisplatin 44-53 peroxisome proliferator activated receptor alpha Mus musculus 66-75 34226503-7 2021 Tet2 KO was associated with a change in metabolic pathways like retinol, arachidonic acid, linolenic acid metabolism, and PPAR signaling pathway in the cisplatin-induced mice model. Cisplatin 152-161 peroxisome proliferator activated receptor alpha Mus musculus 122-126 35367536-0 2022 Melatonin attenuates cisplatin-induced acute kidney injury in mice: Involvement of PPARalpha and fatty acid oxidation. Cisplatin 21-30 peroxisome proliferator activated receptor alpha Mus musculus 83-92 35367536-4 2022 Moreover, melatonin administration protected kidney tissue by significantly upregulating the levels of PPARalpha reduced by cisplatin injection, resulting in increased FAO pathway-associated genes (PGC-1a, Acadm, Acat1, Acsm2, Acsm3, Bdh2, Echs and Pecr) as well as reducing protein levels of caspase-3, -9 and Bax. Cisplatin 124-133 peroxisome proliferator activated receptor alpha Mus musculus 103-112 35367536-6 2022 Our findings suggest that melatonin prevents cisplatin-induced acute kidney injury in mice, possibly by upregulating the expression of PPARalpha, resulting in enhanced FAO and anti-apoptotic properties. Cisplatin 45-54 peroxisome proliferator activated receptor alpha Mus musculus 135-144